Mishra P K, Kahle E H, Bettendorf A F, Dailey J W, Jobe P C
Department of Basic Sciences, University of Illinois College of Medicine, Peoria 61656.
Life Sci. 1993;52(17):1435-41. doi: 10.1016/0024-3205(93)90067-d.
Pharmacological and neurochemical evidence indicates that brain noradrenergic systems play an important role in the determination of audiogenic seizure severity in genetically epilepsy-prone rats (GEPRs). In earlier studies, intracerebroventricular (ICV) injections of norepinephrine suppressed convulsions in a now extinct moderate seizure GEPR colony. Also, ICV noradrenergic agonists are known to produce dose-related anticonvulsant effects in the extant moderate seizure GEPRs (GEPR-3s). The present experiments were undertaken to determine whether ICV norepinephrine also suppresses audiogenic seizures in the extant GEPR-3s and in the severe seizure genetically epilepsy-prone rats (GEPR-9s). Injections of norepinephrine or vehicle were made into the lateral ventricle through implanted guides. GEPR-9s were pretreated systemically either with the monoamine oxidase inhibitor pargyline or with saline. GEPR-3s received no pretreatment. In pargyline pretreated GEPR-9s, seizure severity fell and the fraction of animals exhibiting an anticonvulsant response increased progressively as the dose of norepinephrine was increased. In saline pretreated GEPR-9s, the anticonvulsant dose response curve for norepinephrine was shifted to a higher dose range. Accordingly, the anticonvulsant dose50 for norepinephrine was significantly greater in saline pretreated GEPR-9s than in pargyline pretreated animals. Moreover, the dose required to produce the anticonvulsant effect in GEPR-9s was approximately 10 fold greater than in the earlier studies in the extinct moderate seizure GEPRs. Also, the current experiment with extent GEPR-3s, showed that ICV norepinephrine was anticonvulsant in the same dose that was effective in the extinct colony of moderate seizure GEPRs. In general terms, these observations provide additional evidence that noradrenergic influences are anticonvulsant in the GEPR. The neurobiological factors responsible for reduced responsiveness of the GEPR-9 are presently unknown.
药理学和神经化学证据表明,脑去甲肾上腺素能系统在遗传性癫痫易感大鼠(GEPRs)听源性惊厥严重程度的决定中起重要作用。在早期研究中,脑室内(ICV)注射去甲肾上腺素可抑制现已灭绝的中度惊厥GEPR群体中的惊厥发作。此外,已知ICV去甲肾上腺素能激动剂在现存的中度惊厥GEPRs(GEPR - 3s)中产生剂量相关的抗惊厥作用。本实验旨在确定ICV去甲肾上腺素是否也能抑制现存的GEPR - 3s和严重惊厥遗传性癫痫易感大鼠(GEPR - 9s)中的听源性惊厥。通过植入的导管将去甲肾上腺素或赋形剂注入侧脑室。GEPR - 9s全身预先用单胺氧化酶抑制剂帕吉林或生理盐水处理。GEPR - 3s未接受预处理。在帕吉林预处理的GEPR - 9s中,随着去甲肾上腺素剂量增加,惊厥严重程度降低,出现抗惊厥反应的动物比例逐渐增加。在生理盐水预处理的GEPR - 9s中,去甲肾上腺素的抗惊厥剂量反应曲线向更高剂量范围移动。因此,生理盐水预处理的GEPR - 9s中去甲肾上腺素的抗惊厥剂量50显著高于帕吉林预处理的动物。此外,在GEPR - 9s中产生抗惊厥作用所需的剂量比早期在现已灭绝的中度惊厥GEPRs研究中大约高10倍。同样,目前对现存GEPR - 3s的实验表明,ICV去甲肾上腺素在与现已灭绝的中度惊厥GEPR群体中有效的相同剂量下具有抗惊厥作用。一般来说,这些观察结果提供了额外的证据,表明去甲肾上腺素能影响在GEPR中具有抗惊厥作用。目前尚不清楚导致GEPR - 9反应性降低的神经生物学因素。